Updated just now · Live
Stock analysis, price data, and AI-powered insights for Fate Therapeutics Inc (FATE).
Fate Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for FATE.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). FATE Stock Intelligence Report. [stoxpulse.com/stocks/fate]
Disclaimer: The information on this page about Fate Therapeutics Inc (FATE) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Fate Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Fate Therapeutics Announces Data Presentation of F...
4d ago
Fate Therapeutics Says Preclinical Data From Next-...
5d ago
StoxPulse AI results for FATE: Pulse Score 51/100. Primary sentiment trends from 2 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$161.6M
P/E Ratio
—
EPS
$-0.27
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting